Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis...
CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple...
Barchart Research What to Expect from CRSP Earnings CRSP Generated May 4, 2026 Current Price $53.58 EPS Estimate $$-1.14 Consensus Rating Moderate Buy Average Move 3.85% CRISPR Therapeutics Approaches...
Biotech M&A is surging ahead of a $300B patent cliff. Here are 3 gene-editing stocks investors are watching as potential acquisition targets
Cathie Wood’s ARK Invest is giving retail investors a rare shot at OpenAI, bringing pre-IPO AI exposure into ARKK, ARKW, and ARKF
With $116 million in FY2025 product revenue and a $2.0 billion cash reserves, CRSP has separated itself from pre-commercial peers — but the path forward demands clear eyes on both opportunity and risk....
Cathie Wood recently added to her position in CRISPR Therapeutics stock.
Get context for CRISPR Therapeutics’ Q4 results: CASGEVY launch economics, cash runway, pipeline upside, and the technical level investors should watch.
Scientists are testing an entirely new way to fight heart disease: whether gene editing might offer a one-time fix for high cholesterol
CRISPR Therapeutics is the subject of strong buyout speculation after earning FDA approval for a breakthrough gene-editing therapy.